Centro Specialistico Veterinario, Milan, Italy.
School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
J Vet Intern Med. 2023 Jan;37(1):247-257. doi: 10.1111/jvim.16623. Epub 2023 Jan 27.
Tonsillar carcinomas are rarely reported in dogs. Information on outcome after treatment is sparse and prognosis is guarded to poor.
HYPOTHESIS/OBJECTIVES: Assess treatment outcome and potential prognostic factors in a population of dogs with cytological or histopathological diagnosis of tonsillar carcinoma.
A total of 123 client-owned dogs with diagnosis of tonsillar carcinoma confirmed by cytology or histopathology.
Retrospective, multi-institutional study. Medical records of 12 institutions were reviewed from 2012 to 2021.
Treatment included surgery, chemotherapy (conventional, tyrosine kinase inhibitors or metronomic chemotherapy), radiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) or a combination of these. Surgery was performed in 68 cases, chemotherapy was administered in association with NSAIDs in 64 cases, NSAIDs were used alone in 14 cases and in association with surgery in 21 cases, whereas radiotherapy was used alone or in combination with surgery or chemotherapy in 20 cases. Overall survival time (OST) was 126 days (95% confidence interval [CI], 88-164). Significantly longer survival (P < .001) was seen in dogs without evidence of metastatic disease (median survival time, 381 days; 95% CI, 116-646). Other significant positive prognostic factors included absence of clinicals signs at presentation, surgery (tonsillectomy), use of adjuvant chemotherapy and use of NSAIDs.
Asymptomatic dogs, those treated with surgery, those that received adjuvant chemotherapy, and those that received NSAIDs may have a better prognosis than previously expected, but overall survival remains short for dogs with tonsillar carcinoma.
扁桃体癌在犬中很少见报道。关于治疗后结果的信息很少，预后被认为是差的。
假设/目的：评估经细胞学或组织病理学诊断为扁桃体癌的犬群的治疗结果和潜在的预后因素。
共有 123 只经细胞学或组织病理学诊断为扁桃体癌的患犬。
回顾性、多机构研究。对 12 家机构的病历进行了回顾，时间范围为 2012 年至 2021 年。
治疗包括手术、化疗（常规、酪氨酸激酶抑制剂或节拍化疗）、放疗、非甾体抗炎药（NSAIDs）或这些药物的组合。68 例进行了手术，64 例在 NSAIDs 联合下进行了化疗，14 例单独使用 NSAIDs，21 例与手术联合使用，20 例单独或联合手术或化疗使用了放疗。总生存时间（OS）为 126 天（95%置信区间[CI]，88-164）。无转移疾病证据的犬生存时间明显更长（P<0.001；中位生存时间为 381 天；95%CI，116-646）。其他显著的阳性预后因素包括就诊时无临床症状、手术（扁桃体切除术）、辅助化疗和 NSAIDs 的使用。
无症状犬、接受手术治疗的犬、接受辅助化疗的犬和使用 NSAIDs 的犬的预后可能比以前预期的要好，但患有扁桃体癌的犬的总体生存时间仍然较短。
